Ayala Pharmaceuticals Inc (ADXS)
0.5305
-0.02
(-3.55%)
USD |
OTCM |
May 07, 09:37
Ayala Pharmaceuticals Enterprise Value: 26.69M for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 26.69M |
| May 03, 2024 | 26.90M |
| May 02, 2024 | 25.86M |
| May 01, 2024 | 30.65M |
| April 30, 2024 | 31.58M |
| April 29, 2024 | 31.58M |
| April 26, 2024 | 26.90M |
| April 25, 2024 | 26.69M |
| April 24, 2024 | 26.26M |
| April 23, 2024 | 26.26M |
| April 22, 2024 | 27.62M |
| April 19, 2024 | 27.62M |
| April 18, 2024 | 27.54M |
| April 17, 2024 | 30.75M |
| April 16, 2024 | 28.86M |
| April 15, 2024 | 29.71M |
| April 12, 2024 | 31.71M |
| April 11, 2024 | 31.71M |
| April 10, 2024 | 29.24M |
| April 09, 2024 | 29.24M |
| April 08, 2024 | 31.71M |
| April 05, 2024 | 29.11M |
| April 04, 2024 | 29.11M |
| April 03, 2024 | 29.97M |
| April 02, 2024 | 30.52M |
| Date | Value |
|---|---|
| April 01, 2024 | 30.52M |
| March 28, 2024 | 30.52M |
| March 27, 2024 | 33.07M |
| March 26, 2024 | 33.50M |
| March 25, 2024 | 30.09M |
| March 22, 2024 | 28.82M |
| March 21, 2024 | 28.39M |
| March 20, 2024 | 28.82M |
| March 19, 2024 | 29.76M |
| March 18, 2024 | 28.70M |
| March 15, 2024 | 29.67M |
| March 14, 2024 | 31.80M |
| March 13, 2024 | 33.07M |
| March 12, 2024 | 34.78M |
| March 11, 2024 | 33.93M |
| March 08, 2024 | 36.15M |
| March 07, 2024 | 36.91M |
| March 06, 2024 | 35.20M |
| March 05, 2024 | 35.83M |
| March 04, 2024 | 39.06M |
| March 01, 2024 | 42.06M |
| February 29, 2024 | 39.93M |
| February 28, 2024 | 39.93M |
| February 27, 2024 | 39.93M |
| February 26, 2024 | 41.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-3.208M
Minimum
Sep 28 2023
1.394B
Maximum
Feb 17 2021
225.68M
Average
63.92M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.696M |
| Palatin Technologies Inc | 22.79M |
| iBio Inc | 16.80M |
| Theriva Biologics Inc | -13.36M |
| Oragenics Inc | 3.261M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.67M |
| Total Expenses (Quarterly) | 8.78M |
| EPS Diluted (Quarterly) | -2.081 |
| Earnings Yield | -1.65K% |
| Normalized Earnings Yield | -2164.00 |